Table 1:
Baseline characteristics of participants.
| Baseline characteristics | Total (n = 200) | Tixagevimab–cilgavimab group (n = 100) | Control group (n = 100) | P-value |
|---|---|---|---|---|
| Age, years, mean (SD) | 66.0 (15.6) | 66.2 (14.9) | 65.8 (16.3) | .94 |
| Male sex, n (%) | 93 (46.5) | 39 (39.0) | 54 (54.0) | .03a |
| Weight, kg, mean (SD) | 61.1 (14.3) | 62.3 (16.6) | 60.0 (11.6) | .26 |
| Body-mass index, kg/m2, mean (SD) | 23.0 (4.3) | 23.3 (4.8) | 22.7 (3.7) | .97 |
| Dialysis modality, n (%) | ||||
| Hemodialysis | 169 (84.5) | 82 (82.0) | 87 (87.0) | .33 |
| Peritoneal dialysis | 31 (15.5) | 18 (18.0) | 13 (13.0) | |
| Anuria, n (%) | 71 (35.5) | 40 (40.0) | 31 (31.0) | .18 |
| Cause(s) of ESKD, n (%) | .92 | |||
| Diabetic nephropathy | 83 (41.5) | 40 (40.0) | 43 (43.0) | |
| Hypertensive nephropathy | 46 (23.0) | 23 (23.0) | 23 (23.0) | |
| Glomerulonephritis | 23 (11.5) | 13 (13.0) | 10 (10.0) | |
| Others | 48 (24.0) | 24 (24.0) | 24 (24.0) | |
| Comorbidities, n (%) | ||||
| Hypertension | 193 (96.5) | 98 (98.0) | 95 (95.0) | .25 |
| Dyslipidemia | 140 (70.0) | 70 (70.0) | 70 (70.0) | 1.00 |
| Diabetes mellitus | 101 (50.5) | 51 (51.0) | 50 (50.0) | .89 |
| Coronary artery disease | 41 (20.5) | 17 (17.0) | 24 (24.0) | .22 |
| Cerebrovascular disease | 18 (9.0) | 8 (8.0) | 10 (10.0) | .62 |
| Congestive heart failure | 15 (7.5) | 6 (6.0) | 9 (9.0) | .42 |
| Chronic obstructive pulmonary disease | 2 (1.0) | 1 (1.0) | 1 (1.0) | .75 |
| Cancer | 22 (11.0) | 7 (7.0) | 15 (15.0) | .07 |
| Age-adjusted Charlson comorbidity index, mean (SD) | 5.7 (2.1) | 5.5 (1.9) | 5.9 (2.3) | .24 |
| Previous COVID-19, n (%) | 62 (31.0) | 31 (31.0) | 31 (31.0) | 1.00 |
| Completed extended primary COVID-19 vaccination (≥3 doses), n (%) | 177 (88.5) | 94 (94.0) | 83 (83.0) | .02a |
| Doses of COVID-19 vaccine received, median (IQR) | 4 (3–5) | 4 (3–5) | 3 (3–4) | .01a |
| mRNA COVID-19 vaccine, n (%) | 183 (91.5) | 92 (92.0) | 91 (91.0) | .80 |
| Laboratories | ||||
| Hemoglobin, g/dL, mean (SD) | 10.7 (1.3) | 10.8 (1.1) | 10.6 (1.4) | .22 |
| White blood cell count, ×109/L, mean (SD) | 6.4 (2.2) | 6.6 (2.1) | 6.1 (2.3) | .04a |
| Percentage of neutrophil, %, mean (SD) | 64.9 (8.9) | 65.1 (9.4) | 64.9 (8.7) | .82 |
| Percentage of lymphocyte, %, mean (SD) | 22.2 (7.3) | 21.5 (7.3) | 22.9 (7.3) | .11 |
| Blood urea nitrogen, mg/dL, mean (SD) | 59.4 (19.6) | 60.8 (17.9) | 57.7 (21.1) | .31 |
| Sodium, mmol/L, mean (SD) | 137.2 (3.2) | 137.6 (2.8) | 136.9 (3.5) | .16 |
| Potassium, mmol/L, mean (SD) | 4.4 (0.7) | 4.6 (0.6) | 4.3 (0.7) | .01a |
| Albumin, g/L, mean (SD) | 38.0 (5.3) | 39.2 (5.2) | 36.8 (5.2) | <.01a |
| Intact parathyroid hormone, pg/mL, median (IQR) | 339.0 (166.0–523.0) | 347.6 (178.7–658.4) | 311.0 (165.0–463.0) | .30 |
| Serum ferritin, ng/mL, median (IQR) | 474.0 (234.0–749.3) | 398.3 (212.8–697.0) | 545.5 (265.5–823.5) | .09 |
| Anti-SARS-CoV-2 spike RBD IgG Ab levels, BAU/mL, median (IQR) | 5827.5 (2103.8–18086.1) | 6294.2 (2833.4–19413.6) | 5722.7 (1693.4–17021.8) | .30 |
Data are presented as mean and standard deviation (SD) unless otherwise specified. Baseline characteristics were compared between groups. Continuous variables were assessed using Student's t-test for normally distributed data and the Mann–Whitney U test for non-normally distributed data. Categorical variables were compared using Fisher's exact test.
a
P-value <.05.
The body mass index was calculated from weight in kilograms divided by height squared; anuria was defined as passing urine output below 100 mL per day; total Kt/VUrea represented total small-solute urea clearances.
BAU, binding antibody units.